Big Pharma Supports World's Largest Genetics Project

GALWAY, IRELAND--September 30, 2019--Written by Martin Lynch, European News Editor for Industrial Info (Galway, Ireland)--Some of the world's largest pharmaceutical companies have committed £100 million ($124 million) to a ground-breaking genetics research project designed to tackle a wide range of common and chronic diseases including dementia, mental illness, cancer and heart disease.

Within this article: Details scope of genetics project, partners, 2020 deadline for release of first data

Companies featured: Amgen (NASDAQ:AMGN), AstraZeneca plc (NYSE:AZN), GlaxoSmithKline plc (NYSE:GSK), Johnson & Johnson (NYSE:JNJ)